A high-activity UK & EU sector, led by NHS ENGLAND, most recent listing 5 months ago.
Clinical services, medical equipment, pharmaceuticals, NHS contracts, and health research.
MRC-funded program providing academic researchers access to AstraZeneca's two million-molecule library and advanced screening facilities to discover potential drug candidates.
This contract opportunity involves establishing non-exclusive discount agreements for the drug Fampridine, as per German law. The agreements will be made available through an Open House model, allowing all interested pharmaceutical companies to participate if they meet the requirements. There will b
The KKH (Kaufmännische Krankenkasse) aims to establish discount agreements with all suitable pharmaceutical companies for the specified active ingredients under the Open-House procedure as per § 130a Abs. 8 SGB V. This process allows all eligible and interested pharmaceutical companies or groups to
This contract involves a non-exclusive discount agreement for the pharmaceutical substances Adapalene and Benzoyl Peroxide, classified under ATC code D10AD23. The agreement is established under Section 130a, Paragraph 8 of the German Social Code (SGB V), allowing health insurance funds and pharmaceu
This is not a standard open procedure but an open-house model! The form for the open procedure is used only because there is no form for the open-house model. Contracts made under the open-house model are not subject to procurement law due to the lack of a selection decision. The AOK Bayern intends
This contract opportunity involves the establishment of non-exclusive discount contracts for the medication Glatiramer Acetate, specifically for pre-filled syringes. The contracts will be in effect from February 1, 2026, to January 31, 2028, with the option for suppliers to enter into contracts at a
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical Alfacalcidol, in accordance with specific regulations, for the period from February 1, 2026, to January 31, 2028. Suppliers can enter into contracts at any time during this period, followi
This contract opportunity involves the establishment of non-exclusive discount contracts for the pharmaceutical products Naproxen and Esomeprazole, in accordance with German social law. The contracts will be valid from February 1, 2026, to January 31, 2028, and suppliers can enter into contracts at
This contract opportunity involves the establishment of non-exclusive discount contracts for the medications Olmesartan and Hydrochlorothiazide. These contracts will be in effect from February 1, 2026, to January 31, 2028, and can be signed at any time during this period (open-house model). Please n
This contract opportunity involves the establishment of non-exclusive discount agreements for finished medications containing the active ingredient Timolol (ATC: S01ED01) under an 'open-house model'. All eligible and interested pharmaceutical companies or consortia are invited to enter into or join
